TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants legally competent to sign and give informed consent and, if appropriate, assent as required by local laws.~2. Males and females, ages 6 years and older at time of signing Informed Consent (Screening). Only subjects 18 years and older will be enrolled at sites located in the province of Québec in Canada.~3. Diagnosed with atopic dermatitis 6 months duration (3 months for children), as determined by the Investigator. Stable disease for the past 4 weeks with no significant flares in atopic dermatitis before screening.~4. Females of childbearing potential (FOCBP) must have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Baseline/Day 1. In addition, sexually active FOCBP must agree to use at least one form of a highly effective or barrier method of contraception throughout the trial.~5. In good health as judged by the Investigator.~6. Subjects considered reliable and capable of adhering to the Protocol and visit schedule, according to the judgment of the Investigator.~Exclusion Criteria:~1. Subjects with any serious medical condition or clinically significant abnormality that would prevent study participation or place the subject at significant risk, as judged by the Investigator~2. Has unstable AD or any consistent requirement for high potency topical steroids.~3. Subjects who are unwilling to refrain from prolonged sun exposure and from using a tanning bed or other artificial light emitting devices (LEDs) for 4 weeks prior to Baseline/Day 1 and during the study.~4. Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.~5. Previous treatment with ARQ-151.~6. Subjects with a history of chronic alcohol or drug abuse within 6 months prior to Screening.~7. Parent(s)/legal guardian(s) who are unable to communicate, read, or understand the local language(s). Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.~8. Subjects who are family members of the clinical study site, clinical study staff, or sponsor, or family members of enrolled subjects living in the same house.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Roflumilast Cream 0.15% (Type: EXPERIMENTAL): Participants apply roflumilast cream 0.15% once daily (qd) for 4 weeks.
- Vehicle Cream (Type: PLACEBO_COMPARATOR): Participants apply vehicle cream qd for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria (all subjects)~* Psoriasis vulgaris on trunk and/or limbs affecting at least 2% BSA.~* Psoriasis vulgaris on the scalp affecting at least 10% of total scalp area.~* A total psoriatic involvement on trunk, limbs and scalp not exceeding 30% BSA.~* PGA score of at least mild on trunk and/or limbs at SV1, SV2 and V1.~* PGA score of at least mild on scalp at SV1, SV2 and V1.~* A serum albumin-corrected calcium below the upper reference limit at SV2.~Inclusion Criteria (for subjects performing HPA axis assessment)~* Psoriasis vulgaris on trunk and/or limbs affecting at least 10% BSA.~* Psoriasis vulgaris on the scalp affecting at least 20% of total scalp area.~* PGA score of at least moderate on trunk and limbs at SV1, SV2 and V1.~* PGA score of at least moderate on scalp at SV1, SV2 and V1.~* Normal HPA axis function at SV2 (serum cortisol concentration above 5 mcg/dl before ACTH challenge and serum cortisol concentration above 18 mcg/dl 30 minutes after ACTH challenge).~Exclusion Criteria (all subjects):~* A history of hypersensitivity to any component of LEO 90100.~* Systemic treatment with biological therapies (marketed or not marketed), with a possible effect on scalp and/or body psoriasis within the following time period prior to V1 and during the trial:~  1. etanercept - within 4 weeks prior to V1~ 2. adalimumab, infliximab - within 2 months prior to V1~ 3. ustekinumab - within 4 months prior to V1~ 4. experimental products - within 4 weeks/5 half-lives (whichever is longer) prior to V1~* Systemic treatment with therapies other than biologicals, with a possible effect on scalp and/or body psoriasis (e.g. methotrexate, retinoids, immunosuppressants) within 4 weeks prior to V1 or during the trial.~* PUVA therapy within 4 weeks prior to V1.~* UVB therapy within 2 weeks prior to V1 or during the trial.~Exclusion Criteria (for subjects performing HPA axis assessment):~* A history of serious allergy, allergic asthma or serious allergic skin rash.~* Known or suspected hypersensitivity to any component of CORTROSYN® (including ACTH/cosyntropin/tetracosactide)~* Systemic treatment with corticosteroids (including inhaled and nasal steroids) within 12 weeks prior to SV2 or during the trial.~* Oestrogen therapy (including contraceptives) or any other medication known to affect cortisol levels or HPA axis integrity within 4 weeks prior to SV2 or during the trial.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- LEO 90100 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Locally Delivered Atorvastatin & Rosuvastatin for Treatment of Furcation Defects in Chronic Periodontitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Systemically healthy patients with mandibular class II furcation defects and asymptomatic endodontically vital mandibular molars with radiolucency in furcation area with PD ≥ 5mm and horizontal PD ≥ 3mm and with no history of antibiotic or any periodontal therapy in past 6 months were included in the study~Exclusion Criteria:~* Subjects with any known systemic disease, allergic to statins, on systemic statin therapy, alcoholics, tobacco users, pregnant or lactating women

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- group 1 (Type: PLACEBO_COMPARATOR): Scaling and root planing (SRP) followed by placebo gel local drug delivery
- group 2 (Type: ACTIVE_COMPARATOR): SRP followed by 1.2% rosuvastatin (RSV) gel
- group 3 (Type: ACTIVE_COMPARATOR): SRP followed by 1.2% Atorvastatin (ATV) gel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Developing an Online Therapeutic Intervention for Chronic Pain in Veterans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Current diagnosis of non-cancer chronic pain, defined as:~  * at least one pain-related diagnosis indicated by an ICD-9 or -10 code related to either Musculoskeletal pain or Joint Problems/Osteoarthritis~ * or presence of chronic pain of at least mild to moderate severity as indicated by two or more NRS pain scores of 4 at three separate VA outpatient visits in past year based on a CPRS record review;~* Has a working, high-speed wireless internet connection at home, or is willing to access sessions either at the Bedford VAMC by using a tablet in a secure space~* Competent to provide written informed consent~Exclusion Criteria:~* Any current or lifetime DSM-5 psychotic disorder~* Current or recent (within 1 month of study entry) DSM-5 alcohol or drug use disorder~* \[Current use of any other chronic pain-related behavioral or psychological treatment\]~* Any cognitive impairment that would interfere with study participation~* Clinically significant suicidality within the past year~* Presence of any clinical features requiring a higher level of care (inpatient or partial hospital treatment)~* Any cognitive or physical impairment that would interfere with study participation of using a tablet/computer and providing feedback

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Waitlist Control Group (Type: NO_INTERVENTION): Veterans in the waitlist control will be provided with a list of common pain resources at the Bedford VAMC.
- VACT-CP Group (Type: EXPERIMENTAL): Veterans randomized to VACT-CP will receive 7 online-module based weekly sessions of treatment via personal computer or provided tablet with wireless accessibility at the Bedford VAMC.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Exercise on Migraine Attacks in Chronic Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of chronic migraine confirmed by a specialist neurologist according to ICHD-3B~* No obstacle to exercise in the evaluation made with physical examination and ECG~* Diagnosed with migraine for at least 12 months~* Between the ages of 18-50~Exclusion Criteria:~* Exercising regularly in the last 6 months~* Presence of concomitant internal and neurological diseases~* Anti-psychotic drug use~* Drug, alcohol addiction~* Pregnancy, breastfeeding~* Patients who cannot reach the targeted exercise level

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Combined exercise group (Type: EXPERIMENTAL): Aerobic plus resistance exercise intervention
- Aerobic exercise group (Type: EXPERIMENTAL): Only aerobic exercise intervention
- Control group (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 50 to 59 years~* Determined by medical history, physical examination and clinical judgement to be eligible for the study~* Able to complete electronic diary~* Available for the 5 year 9 month duration of the study~Exclusion Criteria:~* Previous vaccination with any licensed or experimental pneumococcal vaccine~* Allergic to egg proteins and chicken proteins~* History of Guillian-Barre syndrome~* Vaccination with TIV within 6 months before study start~* Vaccination with diphtheria-containing vaccine within 6 months of study start~* Serious chronic disorders including immunodeficiency or metastatic malignancy~* Known or suspected hypersensitivity to any vaccine or vaccine component

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 59 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: OTHER): arm 1 = TIV +13vPnC at visit 1, placebo at visit 2 then 13vPnC at year 5
- 2 (Type: OTHER): arm 2 = TIV + placebo at visit 1, then 13vPnC at visit 2 and at year 5

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~1. Patients aged 20 years or older at the date of informed consent~2. Patients with body surface area (BSA)\<1.5 m2 at screening~3. Patients with histologically/cytologically confirmed locally advanced or metastatic adenocarcinoma subtype non-small cell lung cancer (NSCLC) after failure of first line platinum-based chemotherapy (patients with non-target lesion only are eligible) First line chemotherapy may include continuation or switch maintenance therapy. One prior adjuvant and/or neoadjuvant chemotherapy is accepted.~4. Patients who have life expectancy of at least 3 months~5. Patients who are Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 at screening~6. Patients obtained written informed consent in accordance with International Conference on Harmonisation-Good Clinical Practice (ICH-GCP)and Japanese GCP~Exclusion criteria:~1. Patients who have received more than one prior line of chemotherapy (i.e., second or third line chemotherapy) for advanced or metastatic NSCLC (Prior monotherapies with an epidermal growth factor receptor tyrosine kinase inhibitors \[EGFR-TKI\]) or anaplastic lymphoma kinase (ALK) inhibitor can be allowed)~2. Patients who have received previous therapy with other vascular endothelial growth factor (VEGF) or vascular endothelial growth factor receptor (VEGFR) inhibitors (other than bevacizumab) for the treatment of NSCLC at any time~3. Patients who have received following treatments within 4 weeks prior to start of study therapy 1) Other investigational drugs 2) Chemo-, hormone-, immunotherapy, or monoclonal antibody.~4. Patients who have received molecular target therapy including EGFR TKIs and ALK inhibitors within 2 weeks prior to start of study therapy~5. Patents who have received radiotherapy within the past 3 months (in the case of limited -field \[e.g. brain or bone metastasis\] radiotherapy with palliative intent), within 2 weeks) prior to start of study therapy~6. Patients who not recovered clinically relevant therapy related toxicities from previous chemotherapy and/or radiotherapy (=CTCAE grade 2 Adverse Event from previous treatment) at screening~further exclusion criteria may be applied

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nintedanib plus Docetaxel (Type: EXPERIMENTAL): patients to receive backbone chemotherapy and nintedanib

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* CHI diagnosis established based on the following:~  1. Hyperinsulinemia: plasma insulin above the limit of detection of the assay documented during an event of hypoglycemia, and/or~ 2. Hypofattyacidemia: plasma free fatty acid \<1.7 mmol/L, and/or~ 3. Hypoketonemia: Beta-hydroxybutyrate \<1.8 mmol/L, and/or~ 4. Glycemic response: an increase in PG of \>30 mg/dL (1.7 mmol/L) after 1 mg IV or intramuscular (IM) glucagon administration~* Male or female, age ≥7 days and \<12 months at screening~* Body weight of ≥2.0 kg (4.4 lbs.)~* Continuous IV glucose requirement to prevent hypoglycemia~Exclusion Criteria:~* Is suspected of having a transient form of CHI (e.g., transient hyperinsulinism due to maternal diabetes or perinatal stress)~* Was born preterm below 34 weeks of gestational age~* Presence of hypertension or hypotension, including circulatory instability requiring supportive medication or presence of pheochromocytoma~* Known or suspected presence of severe brain damage~* Evidence of metabolic, endocrine, or syndromic causes of hypoglycemia not due to hyperinsulinism~* Use of systemic corticosteroids, e.g., hydrocortisone \>20 mg/m2 body surface area or equivalent within 5 days before screening~* Prior use of lanreotide, sirolimus (mechanistic target of rapamycin (mTOR) inhibitors), anti inflammatory biological agents, or other immune modulating agents. Prior use of octreotide is allowed after a minimum of 48 hour washout before randomization.~* Any clinically significant abnormality identified on echocardiogram that in the opinion of the investigator would affect the subject's ability to participate in the trial~* Any recognized clotting or bleeding disorder~* The use of prescription or non-prescription medications known to cause QT prolongation

- Gender: ALL
- Minimum Age: 7 Days
- Maximum Age: 364 Days
- Healthy Volunteers: f

Study Arms:
- dasiglucagon first then placebo (Type: EXPERIMENTAL): 48 hours of dasiglucagon subcutaneous (sc) infusion starting at 10 µg/hour with crossover to 48 hours placebo sc infusion (part 1) followed by 21 days of dasiglucagon sc infusion (part 2).
- placebo first then dasiglucagon (Type: EXPERIMENTAL): 48 hours of placebo sc infusion with crossover to 48 hours dasiglucagon sc infusion starting at 10 µg/hour (part 1) followed by 21 days of dasiglucagon sc infusion (part 2).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of Fluticasone Propionate/Salmeterol Combination Post Emergency Department Visit

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with asthma as determined by ICD-9 codes and asthma drug use~* at least 12 years of age~* discharged from an initial Emergency Department visit within 12 months~Exclusion Criteria:~* Subjects with COPD or treatment for COPD

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluticasone propionate/salmeterol combination ED MD (Type: None): Asthma subjects discharged from an institution after treatment for severe asthma exacerbation that receive fluticasone propionate/salmeterol combination from the ED physician
- Fluticasone propionate/salmeterol combination OP MD (Type: None): Asthma subjects discharged from an institution after treatment for severe asthma exacerbation that receive fluticasone propionate/salmeterol combination from the OP physician

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PROlonGed ExpoSure Sertraline

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is an Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn (OEF/OIF/OND) combat veteran with chronic posttraumatic stress disorder (PTSD) or significant PTSD symptoms (Clinician Administered Posttraumatic Stress Disorder Scale \[CAPS\] \>= 50) of at least 3 months duration~Exclusion Criteria:~* Current, imminent risk of suicide (as indicated on C-SSRS)~* Active psychosis~* Alcohol or substance dependence in the past 8 weeks~* Unable to attend regular appointments~* Prior intolerance or failure of adequate trial of prolonged exposure (PE) or sertraline (SERT) (defined as at least 2 months of SERT at least 100mg/day)~* Medical illness likely to result in hospitalization or for which treatments are contraindicated (based on lab results, medical history and physical exam)~* Serious cognitive impairment (as evidenced by cognitive impairment felt likely to interfere with the ability to participate meaningfully in the study)~* Concurrent antidepressants or antipsychotics~* Pregnant females

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sertraline + enhanced medication management (SERT/EMM) (Type: ACTIVE_COMPARATOR): 24 weeks of sertraline + enhanced medication management
- Prolonged Exposure + sertraline (PE/SERT) (Type: ACTIVE_COMPARATOR): Up to 13 sessions of prolonged exposure therapy + 24 weeks of sertraline
- Prolonged Exposure + placebo (PE/PLB) (Type: ACTIVE_COMPARATOR): Up to 13 sessions of prolonged exposure therapy + 24 weeks of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study for Infliximab (Remicade) in Patients With Active Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who have had ulcerative colitis of at least 3 months' duration at screening~* Patients who have ulcerative colitis confirmed by the biopsy taken at screening~* Patients must have active colitis confirmed during the screening sigmoidoscopy~* Patients must have active disease.~Exclusion Criteria:~* Patients must not be likely to require surgical removal of all or part of the colon within 12 weeks of beginning the study~* Patients must not require, or required within the 2 months prior to beginning the study, surgery for active gastrointestinal bleeding, peritonitis, intestinal obstruction, or intra-abdominal or pancreatic abscess requiring surgical drainage

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete